Medical research

Mitsubishi Electric, Okayama University, and Osaka University Develop Magnetic Particle Imaging Device Capable of Producing Images of Human Brain

Retrieved on: 
Thursday, September 7, 2023

Mitsubishi Electric Corporation (TOKYO: 6503), Okayama University and Osaka University’s Graduate School of Engineering announced today that they have developed a magnetic particle imaging device capable of sensitive imaging of magnetic particles in an area equivalent in size to that of the human brain, in a project supported by the Japan Agency for Medical Research and Development (AMED).

Key Points: 
  • Mitsubishi Electric Corporation (TOKYO: 6503), Okayama University and Osaka University’s Graduate School of Engineering announced today that they have developed a magnetic particle imaging device capable of sensitive imaging of magnetic particles in an area equivalent in size to that of the human brain, in a project supported by the Japan Agency for Medical Research and Development (AMED).
  • The device operates at low frequencies of 1 kHz or less, a world-first, allowing the use of a significantly smaller power supply unit.
  • The utilization of this device to image magnetic particles that bind to amyloid-β, the causative agent of Alzheimer's, will allow the accumulation and distribution of amyloid-β to be quantified.
  • The aim is to allow imaging-based assessments of the likelihood of Alzheimer's developing prior to the onset of the disease.

The Inner Circle Acknowledges, Ian A. Wilson as a Distinguished Healthcare Professional for his contributions to the Biomedical Research and Infectious Disease Fields

Retrieved on: 
Tuesday, September 5, 2023

JOLLA, Calif., Sept. 5, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Ian A. Wilson is acknowledged as a Distinguished Healthcare Professional for his contributions to the Biomedical Research and Infectious Disease Fields.

Key Points: 
  • JOLLA, Calif., Sept. 5, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Ian A. Wilson is acknowledged as a Distinguished Healthcare Professional for his contributions to the Biomedical Research and Infectious Disease Fields.
  • Dr. Wilson pursued higher education at the prestigious University of Edinburgh in Scotland in 1971 where he earned a Bachelor of Science degree in Biochemistry.
  • In this post, he directed a laboratory involved in biomedical research on infectious diseases.
  • He currently serves as a Professor at Scripps Research (formerly The Scripps Research Institute or TSRI) in La Jolla, California.

ReAlta Life Sciences Announces Poster Presentation at the European Respiratory Society 2023 International Congress

Retrieved on: 
Tuesday, September 5, 2023

ReAlta Life Sciences (“ReAlta”), Inc., a clinical-stage biotech company addressing life-threatening rare diseases through harnessing the power of the immune system, today announced that it will be presenting additional clinical data from its Phase 1b trial in healthy volunteers on RLS-0071 at the European Respiratory Society 2023 International Congress taking place in Milan, Italy on 9-13 September, 2023.

Key Points: 
  • ReAlta Life Sciences (“ReAlta”), Inc., a clinical-stage biotech company addressing life-threatening rare diseases through harnessing the power of the immune system, today announced that it will be presenting additional clinical data from its Phase 1b trial in healthy volunteers on RLS-0071 at the European Respiratory Society 2023 International Congress taking place in Milan, Italy on 9-13 September, 2023.
  • RLS-0071, the Company’s complement inhibitor and innate anti-inflammatory product candidate, is being developed as a treatment for hypoxic ischemic encephalopathy and other acute inflammatory and rare diseases.
  • The new data will be presented by Prof. Dr. Jens M. Hohlfeld, Division Director of Airway Research at the Fraunhofer Institute for Toxicology and Experimental Medicine (Hannover, Germany) and lead investigator on the Phase 1b trial.
  • Session 68 (PA608) – From bench to bedside: translational studies in airway diseases

Stowers scientists find evidence of unintended impacts from anti-cancer drugs

Retrieved on: 
Wednesday, August 23, 2023

KANSAS CITY, Mo., Aug. 23, 2023 /PRNewswire/ -- With around 90% of drugs failing to make it to market, the potential for improving efficiency within the drug development industry is clear. Drugs designed to combat cancers suffer similar rates of failure for many reasons. Now, researchers have revealed one reason why certain anti-cancer compounds can cause unexpected side effects. This research could help guide an understanding of why some drugs show more promise than others, providing a new tool that can be used to identify those drugs and drug candidates.

Key Points: 
  • This research could help guide an understanding of why some drugs show more promise than others, providing a new tool that can be used to identify those drugs and drug candidates.
  • Thus, the team found a way to capitalize on this variation and asked how chemotherapy drugs impact the nucleolus, causing nucleolar stress.
  • "In this study, we not only evaluated how anti-cancer drugs alter the appearance of nucleoli, but also identified categories of drugs that cause distinct nucleolar shapes," said Gerton.
  • Drugs often fail in clinical trials due to excessive and unintended toxicity that can be caused by their off-target effects.

Wistar Researchers Discover Potential Target for Gastric Cancers Associated with Epstein-Barr Virus

Retrieved on: 
Tuesday, August 22, 2023

PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .

Key Points: 
  • PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .
  • In the paper, Wistar’s Tempera lab investigates the epigenetic characteristics of gastric cancer associated with the Epstein-Barr Virus: EBVaGC.
  • "Normally, a latent virus that reactivates and starts to kill cells is a bad thing.
  • Because lysis is lethal to cells, the epigenetic reactivation of lysis within gastric cancer associated with EBV offers a promising potential treatment for the specific subset of EBVaGC.

Wistar Researchers Discover Potential Target for Gastric Cancers Associated with Epstein-Barr Virus

Retrieved on: 
Tuesday, August 22, 2023

PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .

Key Points: 
  • PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .
  • In the paper, Wistar’s Tempera lab investigates the epigenetic characteristics of gastric cancer associated with the Epstein-Barr Virus: EBVaGC.
  • "Normally, a latent virus that reactivates and starts to kill cells is a bad thing.
  • Because lysis is lethal to cells, the epigenetic reactivation of lysis within gastric cancer associated with EBV offers a promising potential treatment for the specific subset of EBVaGC.

NanoString Platforms Advance Groundbreaking Studies of Immune Response in Pig-to-Human Organ Transplants

Retrieved on: 
Monday, August 21, 2023

The groundbreaking study featured in the August issue and an accompanying commentary of The Lancet medical journal produced fundamental new data on the first pig-to-human organ transplants.

Key Points: 
  • The groundbreaking study featured in the August issue and an accompanying commentary of The Lancet medical journal produced fundamental new data on the first pig-to-human organ transplants.
  • Scientists used the nCounter Human Organ Transplant Panel , a process NanoString developed with the Banff International Classification Consortium.
  • The GeoMx Digital Spatial Profiler was used next to isolate the immune response to specific regions of the kidney.
  • “We congratulate Dr. Loupy and his extended team on their findings and celebrate the on-going successful studies in humans.”

Firearms deaths among U.S. children continue to spike, Northwell Health study shows over 40 percent increase

Retrieved on: 
Monday, August 21, 2023

New research, led by Northwell Health and the Feinstein Institutes for Medical Research , found a 41.6 percent increase in the firearm death rate among children and adolescents between 2018-2021.

Key Points: 
  • New research, led by Northwell Health and the Feinstein Institutes for Medical Research , found a 41.6 percent increase in the firearm death rate among children and adolescents between 2018-2021.
  • View the full release here: https://www.businesswire.com/news/home/20230821043754/en/
    Dr. Chethan Sathya is the director of Northwell Health’s Center for Gun Violence Prevention.
  • The paper, titled “Trends and Disparities in Firearm Deaths among Children,” showed: From 2018-2021, there was a 41.6 percent increase in the firearm death rate.
  • The time to act is long overdue.”
    Since 2019, Northwell Health has been leading the charge to address gun violence as a public health crisis.

Tivic Health Funded Study Begins Enrollment for Novel Non-Invasive Bioelectronic Approach to Vagus Nerve Stimulation

Retrieved on: 
Wednesday, August 16, 2023

Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that the research study that the company is funding at The Feinstein Institutes for Medical Research has received study approval from the Institutional Review Board (“IRB”) and has initiated study recruitment and enrollment for its novel non-invasive bioelectronic device approach to vagus nerve stimulation.

Key Points: 
  • Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that the research study that the company is funding at The Feinstein Institutes for Medical Research has received study approval from the Institutional Review Board (“IRB”) and has initiated study recruitment and enrollment for its novel non-invasive bioelectronic device approach to vagus nerve stimulation.
  • An IRB is an FDA-registered group that has been formally designated to review and monitor biomedical research involving human subjects.
  • In collaboration with Tivic Health, The Feinstein Institutes for Medical Research has initiated the recruitment and completed the first patient enrollment of subjects in the study.
  • This study may provide greater targeting strategies of stimulation and more control over the types of physiologic effects that result from stimulation.

Tivic Reports Second Quarter 2023 Financial Results

Retrieved on: 
Monday, August 14, 2023

Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced its financial results for the second quarter of 2023 ended June 30, 2023 (“Q2 2023”).

Key Points: 
  • Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced its financial results for the second quarter of 2023 ended June 30, 2023 (“Q2 2023”).
  • Gross profit of 37.5% in the second quarter of 2023, compared to 23.4% in the second quarter of 2022, on total revenue of $60 thousand in the second quarter of 2023 from $123 thousand in the second quarter of 2022.
  • Net loss of $2.1 million in the second quarter of 2023, compared with $3.0 million in the second quarter of 2022.
  • The company’s MD&A and consolidated financial statements for the second quarter ended June 30, 2023, will be filed on August 14, 2023, with the company’s Quarterly Report on Form 10-Q.